Recent Patents on Anti-Cancer Drug Discovery This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms
Recent Pat Anticancer Drug Discov. 2024 Jan 4. doi: 10.2174/0115748928269276231120103256. Online ahead of print.ABSTRACTDigestive system neoplasms are highly heterogeneous and exhibit complex resistance mechanisms that render anti-programmed cell death protein (PD) therapies poorly effective. The tumor microenvironment (TME) plays a pivotal role in tumor development, apart from supplying energy for tumor proliferation and impeding the body's anti-tumor immune response, the TME actively facilitates tumor progression and immune escape via diverse pathways, which include the modulation of heritable gene expression alterations...
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Yuxia Wu Xiangyan Jiang Zeyuan Yu Zongrui Xing Yong Ma Huiguo Qing Source Type: research

Regulating Lipid Metabolism via Mitochondrial Dynamics in Tongue Squamous Cell Carcinoma Cancer Stem Cells
CONCLUSION: This study provides a deeper insight into the alterations of lipid metabolism associated with TSCC CSCs, non-CSCs and CSCs regulated by mitochondrial dynamics and thus serves as a guide toward novel targeted therapies.PMID:38305307 | DOI:10.2174/0115748928275772231226063458 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Fan Wu Suling Chen Siqi Ren Ruixin Wang Yongmei Tan Rongxi Chen Bowen Li Haotian Cao Jinsong Li Source Type: research

SSPH I, A Novel Anti-cancer Saponin, Inhibits EMT and Invasion and Migration of NSCLC by Suppressing MAPK/ERK1/2 and PI3K/AKT/mTOR Signaling Pathways
CONCLUSION: SSPH I inhibited EMT, migration, and invasion of NSCLC cells by suppressing MAPK/ERK1/2 and PI3K/AKT/mTOR signaling pathways, suggesting that the natural compound SSPH I could be used for inhibiting metastasis of NSCLC.PMID:38305308 | DOI:10.2174/0115748928283132240103073039 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Jinling Zhou Jian Luo Rizhi Gan Limin Zhi Huan Zhou Meixian Lv Yinmei Huang Gang Liang Source Type: research

TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification
CONCLUSION: TPD52 is upregulated in UCEC and may be a useful patent for prognostic biomarkers of UCEC, which may have important value for clinical treatment and supervision of UCEC patients.PMID:38305309 | DOI:10.2174/0115748928267447231107101539 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 2, 2024 Category: Cancer & Oncology Authors: Lu Miao Buze Chen Li Jing Tian Zeng Youguo Chen Source Type: research

Screening of Candidate Inflammatory Markers of Epithelial Cells in Hepatocellular Carcinoma Based on Integration Analysis of TCGA/ICGC Databases and Single-cell Sequencing
CONCLUSION: Inflammatory factors CCL7, GPR132, ITGB8, PTAFR, SELL, and VIP influence the inflammatory cascade response in HCC epithelial cells, and their expression correlates with the survival prognosis of HCC patients. Interfering with VIP expression effectively suppresses proliferation, migration, and invasion of HCC cells, as well as inhibiting the occurrence of inflammatory cascade reactions, thus slowing down the progression of hepatocellular carcinoma. Furthermore, compounds NADH and Deferoxamine have the potential to target and bind to the inflammatory protein VIP, highlighting their relevance in potential HCC trea...
Source: Recent Patents on Anti-Cancer Drug Discovery - February 1, 2024 Category: Cancer & Oncology Authors: Zupin Huang Zhuokai Li Xinliang Lv Wei Tan Source Type: research

Statin Use and Hepatocellular Carcinoma Risk: A Comprehensive Meta- Analysis and Systematic Review
CONCLUSION: This meta-analysis found statin use is associated with a significantly lower HCC risk. Statins may be a promising preventive intervention against HCC.PMID:38284728 | DOI:10.2174/0115748928282686231221070441 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 29, 2024 Category: Cancer & Oncology Authors: Mahmood Reza Hashemi Rafsanjani Rasoul Rahimi Saeid Heidari-Soureshjani Mohammad Darvishi Omid-Ali Adeli Saber Abbaszadeh Source Type: research

Updated Progress on Mass Spectrometry Imaging and its Application in Cancer Treatment and Drug Discovery
CONCLUSION: MSI is a convenient, fast and powerful technology that has made great progress in sample preparation, instrumentation, quantitation, and multimodal imaging. MSI has emerged as a powerful technique in various biomedical applications, which has strong potential in cancer detection, treatment, formation mechanism research, discovery of biomarkers, and drug discovery process.PMID:38275033 | DOI:10.2174/0115748928269691231203164021 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 26, 2024 Category: Cancer & Oncology Authors: Mingyue Li Jingna Zhou Tingting Zhang Jingyang Lu Yajie Wang Junyu Liu Xiaoyu Zhang Haixia Chen Source Type: research

Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study
CONCLUSION: The results from our successful case and animal experiments provide new avenues for the treatment of relapsed/refractory large B-cell lymphoma with p53 mutation. Further clinical trials are reuqired to treat CD38-positive lymphoma with the combination of daratumumab and venetoclax.PMID:38265376 | DOI:10.2174/0115748928273058231128073414 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 24, 2024 Category: Cancer & Oncology Authors: Duanhao Gong Jia Gu Kuangguo Zhou Wei Huang Source Type: research

Targeting the Key Signaling Pathways in Breast Cancer: From Molecular Mechanism to Therapeutic Interventions
The objective of this review Topic was to discover new intrinsic and extrinsic molecular pathways. Research focusing on novel signaling pathways that may lead to novel treatments or identifying patients at-risk of not responding to standard therapy approaches were the areas of focus we highlighted. The paper covers the linkage between breast cancer stem cells and cellular signaling, the tumor microenvironment in BC, and the relevance of signaling pathways and their therapeutic interventions. The review also covered patent applications associated with these signaling pathways and their prospects.PMID:38251701 | DOI:10.2174/...
Source: Recent Patents on Anti-Cancer Drug Discovery - January 22, 2024 Category: Cancer & Oncology Authors: Deepika Singh Ankit Sahoo Source Type: research

Curcumin Inhibits the Growth of Hepatocellular Carcinoma via the MARCH1-mediated Modulation of JAK2/STAT3 Signaling
CONCLUSION: Our results demonstrated that curcumin may inhibit the activation of JAK2/STAT3 signaling pathway by downregulating MARCH1 expression, resulting in the growth suppression of HCC. MARCH1 may be a novel target of curcumin in HCC treatment.PMID:38243928 | DOI:10.2174/0115748928261490231124055059 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 20, 2024 Category: Cancer & Oncology Authors: Jiaqi Su Xianbing Liu Xiaoyue Zhao Hongjie Ma Yuzhu Jiang Xu Wang Peiyuan Wang Mingdong Zhao Xuemei Hu Source Type: research

Causal Relationships of Chronic Constipation and Irritable Bowel Syndrome with Digestive Tract Cancers: A Mendelian Randomization Study
CONCLUSION: In summary, genetically predicted constipation was associated with an augmented PAAD risk, and IBS was associated with an increased CRC susceptibility within European cohorts, in agreement with some observational studies. Nevertheless, the causal associations of constipation and IBS with other DTCs remain inconclusive.PMID:38243929 | DOI:10.2174/0115748928283326231229061358 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 20, 2024 Category: Cancer & Oncology Authors: Rencai Fan Jiaqi Zhang Jiaofeng Shen Chenkai Mao Shicheng Li Zhixiang Zhuang Source Type: research

Protective Assessment of Novel (Bncs Formulation) against Brain Tumor
CONCLUSION: These findings indicated that, indeed, Diclofenac induces considerable ROSmediated apoptosis in SH-SY5Y cells, which further intriguingly ameliorated Diclofenacmediated cytotoxic effects on SH-SY5Y cells. This manuscript further collected information about available National and International patents published or granted in preparation of and thereof applications against motor and non-motor brain dysfunctions.PMID:38231063 | DOI:10.2174/0115748928272753231212043701 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 17, 2024 Category: Cancer & Oncology Authors: Anuradha Mishra Afza Ahmad Irfan Ahmad Ansari Rohit Kumar Tiwari Source Type: research

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies
This article aims to provide an extensive summary of the latest discoveries regarding CAR-T cell therapy, encompassing its application across various types of human cancers. Moreover, it will delve into the obstacles that have emerged in recent times, offering insights into the challenges faced by this innovative approach. Finally, it highlights novel therapeutic options in treating hematological and solid malignancies with chimeric antigen receptors T-cell therapies.PMID:38213150 | DOI:10.2174/0115748928277331231218115402 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 12, 2024 Category: Cancer & Oncology Authors: Liu Yangjie Cao Peng Faiza Ahad Syed Aqib Ali Zaidi Tobias Achu Muluh Qiuxia Fu Source Type: research

Identification of Breast Cancer Immune-related Prognostic Characteristics in Tumor Microenvironment
CONCLUSION: Three BRCA subtypes were identified with the immune index, which may help design advanced treatment of BRCA. The data code used for the analysis in this article was available on GitHub (https://github.com/tangzhn/BRCA1.git).PMID:38213151 | DOI:10.2174/0115748928258157231128103337 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 12, 2024 Category: Cancer & Oncology Authors: Zhenning Tang Ling Li Xiaoying Huang Yinbing Zhao Qingyuan Liu Chaolin Zhang Source Type: research